Author response: Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review
We thank Parsons et al. for their interest in our article.1 Parsons et al. indicated concern regarding our reference to reporting bias for pregabalin and note Pfizer’s commitment to publishing company-sponsored research. We appreciate this and have included all available data that met eligibility criteria in our analysis. The results of our search for each drug—including counts of studies completed without available result—can be found in table e-2.1 Concerning the published pooled analysis,2 this included studies that did not meet our eligibility criteria. As a result, the pooled analysis was not included in our review.